High Paying US Jobs, Economic Empowerment


Revitalization of States through Federal Power

"Critical Field" Technology Innovation 


Maximized Profits on R&D and Investments

Prevention of Biochemical and Nuclear Proliferation


Homeland Security Technologies

National Council on Innovative Technology Commercialization

International Council on Innovative Technology Commercialization

Critical Field Innovations

Commercialization Programs

About Us


Early And Accurate Detection of Breast and Other Cancers

Cancer Detection 


u  Earlier detection of the critical signs of breast cancer development is key to successful treatment
u  Mammograms tend to detect cancerous lesions that are well along in the development cycle

u  According to the American Cancer Society, one in eight women in the United States will be diagnosed with breast cancer in her lifetime and early detection is vital for survival

u  An estimated 75 million mammograms are performed annually world wide

u  The Company’s technology is applicable to detection of other forms of cancer

u The Company’s technology has significant future possible applications such as:

rheumatoid arthritis, cardiovascular disease, adult blindness, and many other diseases plus the effectiveness monitoring of anti-angiogenic drug therapies

Value Proposition 


u  Advanced low-cost, non-invasive imaging technology detecting angiogenesis (creation of new blood vessels) associated with cancer development

q       Painless one-minute process, with results immediately available

q       Equipment 60-75% less expensive than digital mammography

q       High sensitivity and specificity rates thereby reducing false positive test results

q       False positive test results from mammography create need for 3 million expensive ($2,500-$5,000) biopsies per year, of which 20% are positive and 80% are negative.

u  Helps to discriminate between malignant and benign lesions – thus reducing unnecessary biopsies

u  Designed to identify breast cancer at its earliest stage of development (potentially years)

q       May allow intervention prior to cancer developing into advanced stages 

Market Opportunity           


u  $4+ billion for augmentation of the mammographic equipment market

q       35,000+ installations; $140k projected price per device  

u  500 million cases of angiogenesis-based diseases per year in Western Nations 

q       At $100 per scan, represents substantial opportunity to practitioners; an exciting new opportunity for equipment providers 

u  Multiple up front and recurring revenues from machines, software, maintenance, upgrades

Commercializing patented, low cost, non-invasive scanning system that detects the vascular elements fundamental to the development of breast cancer, with 98% negative predictive value

" The Company's technology may be able to detect cancer years earlier than other available methods; poised to compete with mammography as a screening tool within three years with the potential to play a major role in a $4 billion plus market

" FDA approval: Four of five steps completed. Final step expected to commence in early 2003, complete in mid-2004. Over 1,400 patients successfully scanned to date. CE mark is in place to ship to EEU countries and elsewhere

" Potential equipment market exceeds $4 billion (assuming 1 scanning system at each of 35,000 existing mammogram installations)

" Growing backlog of international orders

" Estimated 75 million mammograms performed annually worldwide

" Company sells scanning device, software, maintenance, upgrades, creating installed base and growing high margin annuity stream

" Retail price of DOBI scanner is $140,000, compared to $350,000 to $500,000 for digital mammographic systems